Technology ID

Substituted Quinoline Analogs as Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors

Lead Inventor
Yang, Shyh-Ming (NCATS)
Simeonov, Anton (NCATS)
Maloney, David (NCATS)
Martinez, Natalia (NCATS)
Yasgar, Adam (NCATS)
Therapeutic Areas
Infectious Disease
Lead IC
Aldehyde dehydrogenase enzymes (ALDHs) have a broad spectrum of biological activities through the oxidation of both endogenous and exogenous aldehydes. Unbalanced expression levels of ALDHs have been associated with a variety of disease states such as alcoholic liver disease, Parkinson’s disease, obesity, and multiple types of cancers. ALDH1A1 also plays a major role in preserving the tumor microenvironment via differentiation, self-protection, and proliferation of cancer stem cells. The cancer cell stemness is associated with cancer relapse and poor prognosis, raising the potential of ALDH1A1 as an attractive therapeutic target.

We performed a systematic medicinal chemistry optimization and biological characterization of newly designed quinoline series that ultimately led to potent ALDH1A1 inhibitors with excellent enzymatic potency and Aldefluor cellular activity (e.g., MIA PaCa-2, OV-90, HT-29 cancer cell lines), as well as improved pharmacokinetic (PK) properties. This chemotype also demonstrated a high degree of selectivity over other ALDH isozymes (ALDH1A2, ALDH1A3, ALDH1B1, ALDH3A1, and ALDH2) and other dehydrogenases (HPGD and HSD17ß4).

Further development of the series indicated that NCATS-101 and NCATS-102 exhibit low nanomolar potency in both enzymatic and cellular assays, demonstrate target engagement in a cellular thermal shift assay (CETSA), and can inhibit the formation of 3D spheroid cultures of OV-90 ovarian cancer cells. In addition, lead compounds potentiated the cytotoxicity of Paclitaxel in SKOV-3-TR, a Taxol-resistant ovarian cancer cell line, which suggest the potential feasibility of combined treatment with existing cancer drugs. PK studies demonstrated that NCATS-101 and NCATS-102 have good drug exposure via oral administration and should be suitable for in vivo studies or testing in other disease-relevant models.
Commercial Applications
  • Compounds and compositions that inhibit aldehyde dehydrogenases, may be used for the treatment of multiple types of cancers, inflammation, and obesity.
Competitive Advantages
  • In vitro results suggest these ALDH1A1 inhibitors may reduce the toxicity of paclitaxel-eluting stents.
Licensing Contact:
Erwin-Cohen, Rebecca